Monopar Therapeutics reported net income of -$5.32M for the quarter ended Jun 2026. This income statement covers 37 quarters of results from Mar 2017 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Mar2017 | Jun2017 | Sep2017 | Dec2017 | Mar2018 | Jun2018 | Sep2018 | Dec2018 | Mar2019 | Jun2019 | Sep2019 | Dec2019 | Mar2020 | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating items | |||||||||||||||||||||||||||||||||||||
| Research & DevelopmentR&D | 1.48M | 1.83M | 1.98M | 1.68M | 2.08M | 1.73M | 2.10M | 1.65M | 1.59M | 1.32M | 1.04M | 0.97M | 1.13M | 0.98M | 1.52M | 1.64M | 1.73M | 2.59M | 4.77M | ||||||||||||||||||
| Selling, General & AdministrativeSG&A | 0.62M | 0.63M | 0.70M | 0.78M | 0.68M | 0.68M | 0.81M | 0.87M | 0.73M | 0.75M | 0.88M | 0.76M | 0.66M | 0.59M | 1.58M | 1.50M | 1.50M | 1.88M | |||||||||||||||||||
| Other Operating ExpensesOther Opex | -1.00 | ||||||||||||||||||||||||||||||||||||
| Operating ExpensesOpex | 2.09M | 2.46M | 2.68M | 2.46M | 2.76M | 2.41M | 2.91M | 2.53M | 2.33M | 2.07M | 1.91M | 1.72M | 1.79M | 1.57M | 1.52M | 3.22M | 3.23M | 4.09M | 6.64M | ||||||||||||||||||
| Operating IncomeOp. Inc | -2.09M | -2.46M | -2.68M | -2.46M | -2.76M | -2.41M | -2.91M | -2.53M | -2.33M | -2.07M | -1.91M | -1.72M | -1.79M | -1.57M | -3.22M | -3.23M | -4.09M | -6.64M | |||||||||||||||||||
| EBIT | -2.09M | -2.46M | -2.68M | -2.46M | -2.76M | -2.41M | -2.91M | -2.53M | -2.33M | -2.07M | -1.91M | -1.72M | -1.79M | -1.57M | -3.22M | -3.23M | -4.09M | -6.64M | |||||||||||||||||||
| Non-operating items | |||||||||||||||||||||||||||||||||||||
| Non Operating Investment IncomeNon-Op. Investment Inc. | 0.03M | ||||||||||||||||||||||||||||||||||||
| Interest & Investment IncomeInt & Inv Inc | 0.02M | 0.03M | -0.02M | 0.11M | -0.34M | 0.08M | 0.07M | 0.10M | 0.60M | 0.78M | 0.66M | 1.30M | |||||||||||||||||||||||||
| Other Non Operating IncomeOther Non Op Inc. | 0.17M | 0.03M | |||||||||||||||||||||||||||||||||||
| Net income details | |||||||||||||||||||||||||||||||||||||
| EBT | -2.09M | -2.46M | -2.68M | -2.46M | -2.76M | -2.41M | -2.89M | -2.49M | -2.35M | -1.95M | -2.25M | -1.64M | -1.72M | -1.48M | -2.62M | -2.45M | -3.44M | -5.35M | |||||||||||||||||||
| Tax ProvisionsTaxes | 11.14M | 13.27M | |||||||||||||||||||||||||||||||||||
| Profit After TaxPAT | -57.00 | -2.46M | -2.68M | -2.46M | -2.76M | -2.40M | -2.90M | -2.43M | -2.20M | -1.96M | -1.83M | -1.64M | -1.72M | -1.32M | -2.62M | -2.45M | -3.50M | -5.32M | |||||||||||||||||||
| Income from Continuing OperationsIncome (Continuing) | -2.09M | -2.46M | -2.68M | -2.46M | -2.76M | -2.41M | -14.04M | -2.49M | -2.35M | -1.95M | -15.51M | -1.64M | -1.72M | -1.48M | -2.62M | -2.45M | -3.44M | -5.35M | |||||||||||||||||||
| Consolidated Net IncomeConsol Net Inc. | -2.09M | -2.46M | -2.68M | -2.46M | -2.76M | -2.41M | -14.04M | -2.49M | -2.35M | -1.95M | -15.51M | -1.64M | -1.72M | -1.48M | -2.62M | -2.45M | -3.44M | -5.35M | |||||||||||||||||||
| Income towards Parent CompanyParent Net Inc | -2.09M | -2.46M | -2.68M | -2.46M | -2.76M | -2.41M | -14.04M | -2.49M | -2.35M | -1.95M | -15.51M | -1.64M | -1.72M | -1.48M | -2.62M | -2.45M | -3.44M | -5.35M | |||||||||||||||||||
| Net Income towards Common StockholdersNet Income | -2.09M | -2.46M | -2.68M | -2.46M | -2.76M | -2.41M | -14.04M | -2.49M | -2.35M | -1.95M | -15.51M | -1.64M | -1.72M | -1.48M | -2.62M | -2.45M | -3.44M | -5.35M | |||||||||||||||||||
| Additional items | |||||||||||||||||||||||||||||||||||||
| EPS (Basic) | -0.83 | -0.98 | -1.07 | -0.97 | -1.09 | -0.94 | -5.52 | -0.95 | -0.87 | -0.69 | -5.61 | -0.51 | -0.49 | -0.42 | -0.38 | -0.35 | -0.48 | -0.63 | |||||||||||||||||||
| Shares Outstanding | 2.51M | 2.52M | 2.49M | 2.52M | 2.53M | 2.55M | 2.54M | 2.62M | 2.68M | 2.82M | 2.76M | 3.20M | 3.50M | 3.52M | 3.79M | 6.99M | 7.00M | 7.12M | 7.41M | 8.54M | |||||||||||||||||
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 2.52M | 2.52M | 2.52M | 2.52M | 2.54M | 2.57M | 2.59M | 2.64M | 2.78M | 2.84M | 2.98M | 3.50M | 3.52M | 3.53M | 3.79M | 6.12M | 6.13M | 6.66M | 6.69M | 8.54M | |||||||||||||||||
| EBITDA | -2.09M | -2.46M | -2.68M | -2.46M | -2.76M | -2.41M | -2.91M | -2.53M | -2.33M | -2.07M | -1.91M | -1.72M | -1.79M | -1.57M | -3.22M | -3.23M | -4.09M | -6.64M | |||||||||||||||||||
| Tax Rate | -384.99% | -589.92% |